Contrasting Sintx Technologies (NASDAQ:SINT) and Coloplast A/S (OTCMKTS:CLPBY)

Coloplast A/S (OTCMKTS:CLPBY) and Sintx Technologies (NASDAQ:SINT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Coloplast A/S and Sintx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	16.38%	27.29%	9.40%
Sintx Technologies	-483.85%	-203.66%	-104.76%

Valuation and Earnings

This table compares Coloplast A/S and Sintx Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$3.93 billion	N/A	$734.56 million	$0.30	31.23
Sintx Technologies	$2.89 million	2.91	-$11.02 million	($50.56)	-0.06

Coloplast A/S has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

18.4% of Sintx Technologies shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Coloplast A/S and Sintx Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	0	4	0	1	2.40
Sintx Technologies	0	0	1	0	3.00

Sintx Technologies has a consensus target price of $28.00, suggesting a potential upside of 818.03%. Given Sintx Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Coloplast A/S.

Volatility & Risk

Coloplast A/S has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Summary

Coloplast A/S beats Sintx Technologies on 8 of the 14 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.